All In MedTech

FDA Clearance Tracker · P130013-S025

Watchman Left Atrial Appendage Closure (LAAC) Device with Delivery System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 1, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 1, 2019

Approved

Time to decision

84 days

Received Dec 7, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P130013-S025
Device name
Watchman Left Atrial Appendage Closure (LAAC) Device with Delivery System
Applicant location
Maple Grove, MN
Received
Dec 7, 2018
Decided
Mar 1, 2019
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P130013

Device type

Device class
Class III

Every decision under product code NGV

FDA's approval statement

As written in FDA's record.

Approval for approval for a manufacturing site, Synergy Health Ireland Ltd., (a STERIS Company), located at IDA Business and Technology Park, Srah, Tullamore, County Offaly, Ireland, as a new ethylene oxide (EO) sterilization site for the WATCHMAN Left Atrial Appendage Closure (LAAC) Device with Delivery System.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.